Recommended Topic Related To:

Ogen

"The U.S. Food and Drug Administration today approved Brisdelle (paroxetine)to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mes"...

Ogen

Ogen

CLINICAL PHARMACOLOGY

Endogen (estropipate) ous estrogen (estropipate) s are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogen (estropipate) s exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen (estropipate) and is substantially more potent than its metabolites, estrone and estriol at the receptor level. The primary source of estrogen (estropipate) in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogen (estropipate) ous estrogen (estropipate) is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogen (estropipate) s in postmenopausal women.

Estrogen (estropipate) s act through binding to nuclear receptors in estrogen (estropipate) -responsive tissues. To date, two estrogen (estropipate) receptors have been identified. These vary in proportion from tissue to tissue.

Circulating estrogen (estropipate) s modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogen (estropipate) s act to reduce the elevated levels of these hormones seen in postmenopausal women.

Pharmacokinetics

Absorption

Estrogen (estropipate) s are well absorbed through the skin and gastrointestinal tract. When applied for a local action, absorption is usually sufficient to cause systemic effects.

Distribution

The distribution of exogen (estropipate) ous estrogen (estropipate) s is similar to that of endogen (estropipate) ous estrogen (estropipate) s. Estrogen (estropipate) s are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogen (estropipate) s circulate in the blood largely bound to sex hormone binding globulin (SHBG) and albumin.

Metabolism

Exogen (estropipate) ous estrogen (estropipate) s are metabolized in the same manner as endogen (estropipate) ous estrogen (estropipate) s. Circulating estrogen (estropipate) s exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogen (estropipate) s also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogen (estropipate) s exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogen (estropipate) s.

Excretion

Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.

Drug Interactions

In vitro and in vivo studies have shown that estrogen (estropipate) s are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen (estropipate) drug metabolism. Inducers of CYP3A4 such as St. John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogen (estropipate) s, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogen (estropipate) s and may result in side effects.

Clinical Studies

Women's Health Initiative Studies

The Women's Health Initiative (WHI) enrolled a total of 27,000 predominantly healthy postmenopausal women to assess the risks and benefits of either the use of 0.625 mg conjugated estrogen (estropipate) s (CE) per day alone or the use of oral 0.625 mg conjugated estrogen (estropipate) s plus 2.5 mg medroxyprogesterone acetate (MPA) per day compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome studied. A “global index” included the earliest occurrence of CHD, invasive breast cancer, stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, or death due to other cause. The study did not evaluate the effects of CE or CE/MPA on menopausal symptoms.

The CE/MPA substudy was stopped early because, according to the predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the “global index.” Results of the CE/MPA substudy, which included 16,608 women (average age of 63 years, range 50 to 79; 83.9% White, 6.5% Black, 5.5% Hispanic), after an average followup of 5.2 years are presented in Table 1 below:

Table 1: RELATIVE AND ABSOLUTE RISK SEEN IN THE CE/MPA SUBSTUDY OF WHI *

Event † Relative Risk
CE/MPA vs. placebo
at 5.2 Years
(95% CI‡)
Placebo
n = 8102
CE/MPA
n = 8506
Absolute Risk per 10,000 Person-years
CHD events 1.29 (1.02–1.63) 30 37
Non-fatal MI 1.32 (1.02–1.72) 23 30
CHD death 1.18 (0.70–1.97) 6 7
Invasive breast cancer § 1.26 (1.00–1.59) 30 38
Stroke 1.41 (1.07–1.85) 21 29
Pulmonary embolism 2.13 (1.39–3.25) 8 16
Colorectal cancer 0.63 (0.43–0.92) 16 10
Endometrial cancer 0.83 (0.47–1.47) 6 5
Hip fracture 0.66 (0.45–0.98) 15 10
Death due to causes other than the events above 0.92 (0.74–1.14) 40 37
Global index † 1.15 (1.03–1.28) 151 170
Deep vein thrombosis ¶ 2.07 (1.49–2.87) 13 26
Vertebral fractures ¶ 0.66 (0.44–0.98) 15 9
Other osteoporotic fractures ¶ 0.77 (0.69–0.86) 170 131
*adapted from JAMA, 2002; 288:321–333
†a subset of the events was combined in a “global index,” defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes
‡ nominal confidence intervals unadjusted for multiple looks and multiple comparisons
§ includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer
¶ not included in Global Index

For those outcomes included in the “global index,” the absolute excess risks per 10,000 person-years in the group treated with CE/MPA were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10,000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the “global index” was 19 per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. (See BOXED WARNINGS, WARNINGS and PRECAUTIONS.)

Women's Health Initiative Memory Study

The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 years of age and older) to evaluate the effects of CE/MPA (0.625mg conjugated estrogen (estropipate) s plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable dementia (primary outcome) compared with placebo.

After an average follow-up of 4 years, 40 women in the estrogen (estropipate) /progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable dementia. The relative risk of probable dementia in the hormone therapy group was 2.05 (95% CI, 1.21 to 3.48) compared to placebo. Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women. (See BOXED WARNINGS and WARNINGS, Dementia.)

Osteoporosis

The results of a double-blind, placebo-controlled two-year study have shown that treatment with one tablet of OGEN (estropipate) .625 daily for 25 days (of a 31-day cycle per month) prevents vertebral bone mass loss in postmenopausal women. When estrogen (estropipate) therapy is discontinued, bone mass declines at a rate comparable to that of the immediate postmenopausal period. There is no evidence that estrogen (estropipate) replacement therapy restores to premenopausal levels.

Last reviewed on RxList: 4/30/2009
This monograph has been modified to include the generic and brand name in many instances.

A A A

Ogen - User Reviews

Ogen User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Ogen sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations